Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
This Breast Cancer Surveillance Consortium (BCSC) ADVANCE study is a large, observational pragmatic comparative effectiveness research study using high-quality, prospectively collected data from BCSC registries to generate evidence on how breast density should be integrated into decision making around breast cancer screening and preoperative diagnostic work-up. We will augment existing BCSC registry infrastructure with additional prospective data collection and collection of patient reported outcomes (PROs), CISNET modeling of long-term screening outcomes, and qualitative data from focus groups with women represented in two aims.
Description: Number of stage I or IIA cancers diagnosed within 1 year of a positive screen divided by total number of screens
Measure: Screening Benefits: Rate of early stage invasive cancer detection (Aim 1) Time: Within one year after screenDescription: Number of invasive cancer cases within 1 year of a negative screen divided by total number of screens Number of advanced cancers (stage IIB or higher) within 1 year of a screen divided by total number of screens
Measure: Screening Failures: Interval or advanced breast cancer rate (Aim 1) Time: Within one year after screenDescription: Number of positive screens divided by total number of screens
Measure: Screening Harms: Recall rate (Aim 1) Time: Within one year after screenDescription: Number of positive screens without a cancer diagnosed within 1 year divided by total number of screens
Measure: Screening Harms: False-positive (FP) recall rate (Aim 1) Time: Within one year after screenDescription: Number of screens with a biopsy recommendation and no cancer diagnosed within 1 year divided by total number of screens
Measure: Screening Harms: FP biopsy recommendation rate (Aim 1) Time: Within one year after screenDescription: Number of DCIS diagnoses within 1 year of a positive screen divided by total number of screens, reported overall and by grade
Measure: Screening Harms: Other consequences (Aim 1) Time: Within one year after screenDescription: Patient surveys targeted to determining outcomes of interest to patients
Measure: Patient Reported Outcomes (Aim 1) Time: Measured within one year post-screeningDescription: Number of women with contralateral breast cancer diagnosed within 6 months of initial diagnosis over total number of women
Measure: Rates of additional breast cancers detected (Aim 2) Time: 6 months after initial diagnosisDescription: Rate of 2nd breast cancers diagnosed within 3 years of follow-up (starting 6 months after initial diagnosis) calculated separately for ipsilateral and contralateral cancers
Measure: 3-year rate of 2nd breast cancer events (Aim 2) Time: 3 years after initial diagnosisDescription: Patient surveys targeted to determining outcomes of interest to patients
Measure: Patient Reported Outcomes (Aim 2) Time: Measured 6-18 months post-diagnosisDescription: Number of cancer cases within 1 year of positive screen divided by number of breast cancer cases
Measure: Performance Measures: Sensitivity (Aim 1) Time: Within one year after screenDescription: Number of negative screens without cancer diagnosed within 1 year of screen divided by number of screens without breast cancer
Measure: Performance Measures: Specificity (Aim 1) Time: Within one year after screenDescription: Number of cancer cases within 1 year of positive screen divided by number of positive screens
Measure: Performance Measures: Positive predictive value (Aim 1) Time: Within one year after screenDescription: Rates of unilateral mastectomy, or bilateral mastectomy, lumpectomy with reconstruction, lumpectomy without reconstruction
Measure: Definitive surgery type (Aim 2) Time: 6 months after initial diagnosisDescription: Number of women with a negative pre-operative MRI and no additional cancers diagnosed within 6 months after initial diagnosis over the total number of women with a negative pre-operative MRI
Measure: Negative predictive value of work-up with MRI (Aim 2) Time: 6 months after initial diagnosisDescription: Number of women without a pre-operative MRI with no additional cancers diagnosed within 6 months after initial diagnosis over the total number of women without a pre-operative MRI
Measure: Negative predictive value of work-up without MRI (Aim 2) Time: 6 months after initial diagnosisDescription: Number of core biopsies within 6 months of initial diagnosis over number of breast biopsies
Measure: Core biopsy rates (Aim 2) Time: 6 months after initial diagnosisDescription: Number of surgical biopsies within 6 months of initial diagnosis over number of breast biopsies
Measure: Surgical biopsy rate (Aim 2) Time: 6 months after initial diagnosisDescription: Number of initial benign biopsies over number of breast biopsies
Measure: Benign biopsy rate (Aim 2) Time: 6 months after initial diagnosisDescription: Breast cancers deaths averted estimated by the Cancer Intervention and Surveillance Modeling Network (CISNET) models
Measure: Modeled Long-Term Mortality Outcome: Breast cancers deaths averted (Aim 1) Time: From date of first screening examination until the date of death from any cause, up to 100 years of ageDescription: Life-years gained estimated by the Cancer Intervention and Surveillance Modeling Network (CISNET) models
Measure: Modeled Long-Term Mortality Outcome: Life-years gained (Aim 1) Time: From date of first screening examination until the date of death from any cause, up to 100 years of ageDescription: Overdiagnosis estimated by the Cancer Intervention and Surveillance Modeling Network (CISNET) models
Measure: Modeled Long-Term Mortality Outcome: Overdiagnosis (Aim 1) Time: From date of first screening examination until the date of death from any cause, up to 100 years of ageAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports